CN108289843B - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN108289843B
CN108289843B CN201680071126.5A CN201680071126A CN108289843B CN 108289843 B CN108289843 B CN 108289843B CN 201680071126 A CN201680071126 A CN 201680071126A CN 108289843 B CN108289843 B CN 108289843B
Authority
CN
China
Prior art keywords
pharmaceutical composition
budesonide
formoterol
weight
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680071126.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108289843A (zh
Inventor
斯图尔特·科尔
蒂莫西·詹姆斯·诺克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57750288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108289843(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1521456.2A external-priority patent/GB201521456D0/en
Priority claimed from GB1615916.2A external-priority patent/GB2554092A/en
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Priority to CN202011316904.7A priority Critical patent/CN112472689B/zh
Publication of CN108289843A publication Critical patent/CN108289843A/zh
Application granted granted Critical
Publication of CN108289843B publication Critical patent/CN108289843B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680071126.5A 2015-12-04 2016-12-02 药物组合物 Active CN108289843B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011316904.7A CN112472689B (zh) 2015-12-04 2016-12-02 药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1521456.2A GB201521456D0 (en) 2015-12-04 2015-12-04 Pharmaceutical composition
GB1521456.2 2015-12-04
GB1615916.2A GB2554092A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
GB1615916.2 2016-09-19
PCT/GB2016/053812 WO2017093758A1 (en) 2015-12-04 2016-12-02 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011316904.7A Division CN112472689B (zh) 2015-12-04 2016-12-02 药物组合物

Publications (2)

Publication Number Publication Date
CN108289843A CN108289843A (zh) 2018-07-17
CN108289843B true CN108289843B (zh) 2021-08-17

Family

ID=57750288

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011316904.7A Active CN112472689B (zh) 2015-12-04 2016-12-02 药物组合物
CN201680071126.5A Active CN108289843B (zh) 2015-12-04 2016-12-02 药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202011316904.7A Active CN112472689B (zh) 2015-12-04 2016-12-02 药物组合物

Country Status (10)

Country Link
US (3) US11559505B2 (enExample)
EP (4) EP3701940B1 (enExample)
JP (3) JP6899824B2 (enExample)
CN (2) CN112472689B (enExample)
AU (3) AU2016364650B2 (enExample)
BR (2) BR112018011266B1 (enExample)
CA (1) CA3007050C (enExample)
ES (3) ES2796177T5 (enExample)
MX (1) MX375783B (enExample)
WO (1) WO2017093758A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
MX384545B (es) * 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3610877A1 (en) * 2016-09-19 2020-02-19 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
ES2949975T3 (es) 2016-09-19 2023-10-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende indacaterol
CN109771398B (zh) * 2019-02-25 2019-09-20 广州南鑫药业有限公司 一种帕拉米韦溶液型吸入剂及其制备方法
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
PE20221867A1 (es) * 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
CN115087431A (zh) * 2020-02-20 2022-09-20 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
CN116338014A (zh) * 2021-12-23 2023-06-27 上海医药工业研究院有限公司 一种吸入用药物组合物的组分分离检测方法
FR3137830A1 (fr) * 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870090A2 (en) * 2005-03-15 2007-12-26 Laboratorio Aldo-Union, S.A. Novel stable formulation of suspended aerosols and production method thereof
CN101389341A (zh) * 2006-04-21 2009-03-18 奇斯药制品公司 用于加压计量吸入器的药物溶液制剂
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
CN103501776A (zh) * 2011-02-17 2014-01-08 西普拉有限公司 甘罗铵与β2激动剂的组合物
CN103517706A (zh) * 2011-05-13 2014-01-15 墨西哥化学阿玛科股份有限公司 药物组合物
CN104918604A (zh) * 2012-10-23 2015-09-16 西普拉有限公司 药物组合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
JP4155594B2 (ja) 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
WO1996032151A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6461591B1 (en) 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
KR100575070B1 (ko) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1213732C (zh) 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
AR036358A1 (es) 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP4074289B2 (ja) 2002-08-08 2008-04-09 株式会社フジクラ コネクタを備えた信号伝送ケーブルおよびその製造方法
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
AU2007346134A1 (en) 2007-02-09 2008-08-14 Merck Sharp & Dohme Corp. Stable pharmaceutical drug aerosols
US8597616B2 (en) * 2007-10-22 2013-12-03 Board Of Regents Of The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process
EP2482799B1 (en) * 2009-10-02 2014-06-18 Chiesi Farmaceutici S.p.A. Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
DK3089735T3 (en) 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
MX384545B (es) 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870090A2 (en) * 2005-03-15 2007-12-26 Laboratorio Aldo-Union, S.A. Novel stable formulation of suspended aerosols and production method thereof
CN101389341A (zh) * 2006-04-21 2009-03-18 奇斯药制品公司 用于加压计量吸入器的药物溶液制剂
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
CN103501776A (zh) * 2011-02-17 2014-01-08 西普拉有限公司 甘罗铵与β2激动剂的组合物
CN103517706A (zh) * 2011-05-13 2014-01-15 墨西哥化学阿玛科股份有限公司 药物组合物
CN104918604A (zh) * 2012-10-23 2015-09-16 西普拉有限公司 药物组合物

Also Published As

Publication number Publication date
EP3556348B1 (en) 2021-02-03
JP6899824B2 (ja) 2021-07-07
ES2796177T5 (es) 2024-10-29
AU2019202874C1 (en) 2020-08-06
BR112018011266A2 (pt) 2018-11-21
CN112472689A (zh) 2021-03-12
BR122020022602B1 (pt) 2024-03-05
CN112472689B (zh) 2023-01-17
JP2019500340A (ja) 2019-01-10
JP2020073515A (ja) 2020-05-14
EP3383366B2 (en) 2024-06-05
JP6931383B2 (ja) 2021-09-01
CA3007050C (en) 2020-12-08
US11559507B2 (en) 2023-01-24
US20190247339A1 (en) 2019-08-15
US20200069619A1 (en) 2020-03-05
ES2796177T3 (es) 2020-11-26
US11559506B2 (en) 2023-01-24
EP3556347A1 (en) 2019-10-23
CA3007050A1 (en) 2017-06-08
ES2869176T3 (es) 2021-10-25
EP3556347B1 (en) 2021-03-24
ES2866175T3 (es) 2021-10-19
MX375783B (es) 2025-03-07
WO2017093758A1 (en) 2017-06-08
AU2016364650B2 (en) 2019-04-04
EP3383366B1 (en) 2020-03-25
AU2019202874A1 (en) 2019-05-16
EP3701940B1 (en) 2025-11-12
MX2018006800A (es) 2018-11-09
BR112018011266B1 (pt) 2023-11-21
US20200009089A1 (en) 2020-01-09
AU2019202875A1 (en) 2019-05-16
US11559505B2 (en) 2023-01-24
JP2020073516A (ja) 2020-05-14
EP3383366A1 (en) 2018-10-10
EP3556348A1 (en) 2019-10-23
AU2016364650A1 (en) 2018-06-21
JP6899889B2 (ja) 2021-07-07
AU2019202875B2 (en) 2020-03-12
CN108289843A (zh) 2018-07-17
AU2019202874B2 (en) 2020-03-12
EP3701940A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
CN108289843B (zh) 药物组合物
CN108289842B (zh) 药物组合物
CN114272238A (zh) 药物组合物
CN109789131B (zh) 药物组合物
CN113288869A (zh) 药物组合物
GB2554092A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant